Senolytic therapy with dasatanib + quercetin (D + Q) in HFD-induced murine obesity is associated with improvement in cellular senescence markers, insulin sensitivity, metabolic syndrome, metaflammation, WAT macrophage infiltration, and adipogenesis in preclinical studies [204,337]. Here, INS is linked to metabolic syndrome.